---
title: "Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299485166.md"
description: "Neuphoria Therapeutics reported FY2026 revenue of $1.17M, a 92.5% drop from FY2025, due to the absence of a $15M Merck milestone. Net loss widened to $13.59M. R&D paused pending strategic review; operational restructuring reduced headcount and costs to extend cash runway into FY2028. Goodwill was impaired as Merck halted the MK-1167 trial."
datetime: "2026-09-18T20:15:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299485166.md)
  - [en](https://longbridge.com/en/news/299485166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299485166.md)
generator: "portal-rs"
---

# Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary

Neuphoria Therapeutics Inc. reported fiscal year 2026 revenue of $1.17M and a loss before income taxes of $13.59M, reflecting a sharp decline in revenue and a wider loss versus the prior year as milestone income recorded in FY2025 did not recur.

**Financial Highlights**

-   Revenue was $1.17M for the year ended June 30, 2026, down from $15.65M in FY2025; YoY change (92.5%).
-   Loss before income taxes was $13.59M for the year ended June 30, 2026, versus a loss of $0.84M in FY2025 (widened loss YoY).
-   Diluted earnings per share: not reported in MD&A/Item 8 for FY2026 and therefore omitted.

**Business Highlights**

-   Revenue decline driven by absence of a $15.0M milestone from Merck that was recognized in FY2025; smaller CRC-related revenue also contributed to the drop.
-   BNC210 remained the company's core asset, but R&D activity was largely paused in October 2025 pending a strategic review and potential partnership or merger.
-   Ongoing collaborations — including the Merck agreement (milestones, potential royalties) and a Carina license — provide potential non-dilutive milestone opportunities.
-   Operational restructuring in October 2025 reduced headcount, closed facilities and lowered G&A to preserve cash runway into FY2028.
-   Goodwill was impaired after Merck halted the MK-1167 trial, increasing uncertainty around the value of the partnered program.

Original SEC Filing: Neuphoria Therapeutics Inc. \[ NEUP \] - 10-K - Sep. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NEUP.US](https://longbridge.com/en/quote/NEUP.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss](https://longbridge.com/en/news/298558395.md)
- [Neuphoria FY26 loss widens to $13.59 million; revenue drops 92.5% to $1.17 million](https://longbridge.com/en/news/299484388.md)
- [Key facts: Merck (MRK) up on vaccine; policy may hit M-M-R II, ProQuad](https://longbridge.com/en/news/296749142.md)
- [Braun Stacey Associates Inc. Has $35.07 Million Stock Position in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/297397633.md)
- [Merck & Co., Inc. $MRK Shares Purchased by Russell Investments Group Ltd.](https://longbridge.com/en/news/296761195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**